5 Result(s)

Article

Erratum: Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

Correction to: Blood Cancer Journal (2016) 6, e453; doi:10.1038/bcj.2016.64 The purpose of this corrigendum is to publish grant support omitted in the manuscript 16-BCJ-0175T entitled, ‘Dose-dense and less dos...

Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke… in Blood Cancer Journal (2016)

Article

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

Multiple myeloma (MM) is a heterogeneous disease with high-risk patients progressing rapidly despite treatment. Various definitions of high-risk MM are used and we reported that gene expression profile (GEP)-d...

Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke… in Blood Cancer Journal (2016)

Article

Inhibiting MEK in MAPK pathway-activated myeloma

C J Heuck, Y Jethava, R Khan, F van Rhee, M Zangari, S Chavan, K Robbins… in Leukemia (2016)

Article

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

X Papanikolaou, A Rosenthal, M Dhodapkar, J Epstein, R Khan… in Blood Cancer Journal (2016)

Article

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

As part of Total Therapy (TT) 3b, baseline marrow aspirates were subjected to two-color flow cytometry of nuclear DNA content and cytoplasmic immunoglobulin (DNA/CIG) as well as plasma cell gene expression pro...

X Papanikolaou, D Alapat, A Rosenthal, C Stein, J Epstein, R Owens, S Yaccoby… in Leukemia (2015)